215 related articles for article (PubMed ID: 31566022)
1. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
2. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
Fan Y; Hou X; Fang H
Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
5. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
6. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
7. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
8. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
Hird AW; Tron AE
Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
Zhu PJ; Yu ZZ; You QD; Jiang ZY
Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
[TBL] [Abstract][Full Text] [Related]
11. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
13. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
[TBL] [Abstract][Full Text] [Related]
14. An updated patent review of Mcl-1 inhibitors (2020-2022).
Liu J; Yin F; Wang Z; Song T; Zhang Z
Expert Opin Ther Pat; 2023; 33(5):371-383. PubMed ID: 37293764
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
[TBL] [Abstract][Full Text] [Related]
16. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
Pal P; Zhang P; Poddar SK; Zheng G
Expert Opin Ther Pat; 2022 Sep; 32(9):1003-1026. PubMed ID: 35993382
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
18. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors.
Follows B; Fessler S; Baumeister T; Campbell AM; Zablocki MM; Li H; Gotur D; Wang Z; Zheng X; Molz L; Nguyen C; Herbertz T; Wang L; Bair K
Bioorg Med Chem Lett; 2019 Aug; 29(16):2375-2382. PubMed ID: 31235261
[TBL] [Abstract][Full Text] [Related]
20. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]